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Introduction: It has been reported that the chemotherapeutic agent, adriamycin, not only has an effect on the
myocardium but also on the arteries. The aim of this study is to elucidate effects of adriamycin and an angiotensin
receptor blocker, candesartan, on collagen and elastin of the aorta in rats.
Methods: Twenty four male 8-week-old Wistar-Kyoto rats were divided into four groups: control (C) group,
adriamycin-treated (AD) group, candesartan-treated (CA) group, and adriamycin- and candesartan-treated (AD + CA)
group. Adriamycin of 2.5 mg/kg/wk was administered intraperitoneally one time per week for 6 weeks, and
candesartan of 10 mg/kg/day was administered orally everyday for 6 weeks. After 6 weeks, the rats were sacrificed
and the aortas were harvested. Hematoxylin-eosin staining, Verhoff’s elastic, and Goldner’s trichrome staining were
performed for histopathologic analyses. Tunica media thickness, collagen, and elastic area fractions were measured
quantitatively with a computerized digital image analyzer.
Results: Tunica media thickness in the CA and AD + CA groups was significantly lesser than that in the C and AD
groups, respectively. The AD and AD + CA groups had a tendency of lower elastin area fraction than the C and CA
groups, respectively. Collagen area fraction in the AD + CA group was significantly lower than that in the AD group.
There were no significant differences of collagen/elastin ratio between groups.
Conclusions: These findings suggest that adriamycin has a tendency of decreasing the quantity of elastin fibers
and candesartan cannot mitigate the effects of adriamycin on elastin fibers.
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The anthracycline chemotherapeutic agent, adriamycin,
is widely used and effective in many malignancies [1].
However, adriamycin has an important adverse effect,
cardiotoxicity [2]. In practice, oncologists cannot often
continue with the administration of adriamycin because
of adriamycin-induced cardiomyopathy, though adriamy-
cin is effective in inducing remission of cancer.
The aorta has the same embryologic origin as the heart,
and it is anatomically and hemodynamically directly
connected to the heart. The heart and the aorta often
share the same pathophysiology of the diseases including* Correspondence: younhj@catholic.ac.kr
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unless otherwise stated.hypertensive cardiovascular disease. Some researchers
proposed that adriamycin has adverse effects not only on
the heart but also on the arteries [3-5]. However, there
have been not many studies on vascular pathology by
adriamycin, and changes of aorta microstructure by adria-
mycin have not been known in detail. In addition, it has
been reported that angiotensin-converting enzyme inhi-
bitors or angiotensin receptor blockers can alleviate the
fibrotic process [6]. This was a pilot study to investigate
whether adriamycin can have an effect on collagen and
elastin of the aorta in rats and whether candesartan can
mitigate the effects of adriamycin.Methods
Animals
The study protocol was approved by the institutional re-
view board for Animal Research of Yeouido St. Mary’s
Hospital (no: YEOUIDO-2012-13-01). Twenty four maled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schedule of administration of adriamycin and candesartan. ip, intraperitoneally; po, per os; qd, everyday.
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kept in cages under conditions of a room temperature of
20°C, a relative humidity of 60%, and a day/night cycle
of 12 h. The rats had free access to food and water in
cages. The rats were divided into four groups: control
(C), adriamycin-treated (AD), candesartan-treated (CA),
adriamycin- and candesartan-treated (AD + CA). The
rats were weighed at the beginning of the experiment.
In the AD and AD + CA groups, 2.5 mg/kg of adria-
mycin (Ildong Pharmaceuticals Co., Anseong, Korea)
was injected intraperitoneally six times for 6 weeks
(Figure 1) [7]. In the C and CA groups, normal saline of
the same volume was injected by using the same method
at the same time as the AD and AD + CA groups. In the
CA and AD + CA groups, 10 mg/kg/day of candesartan
(AstraZeneca, Zoetermeer, The Netherlands) was admi-
nistered orally with a sonde (Figure 1). In the C and AD
groups, normal saline of the same volume was admi-
nistrated orally by using the same method at the same
time as the CA and AD + CA groups. After 6 weeks, the
rats were weighed and placed under anesthesia by zoletil
(Virbac, Carros, France), the sternum was incised longi-
tudinally, and the heart and the aorta were exposed. The
rats were euthanized by injection of potassium chloride
into both ventricles. After cardiac arrest, the aorta was
extracted from the proximal ascending aorta to bifur-





AD + CA 172.5 (158–174.5)
BW1 body weight before administration of drugs, BW2 body weight after administr
CA candesartan-treated.Staining and light microscopic examination
After the extracted aorta was irrigated with normal saline,
the descending thoracic aorta was cut into small pieces.
These pieces were fixed in 10% neutral-buffered formalin
solution. After the dehydration process, the aortic tissue
sample was embedded into a paraffin block and cut with a
microtome. Hematoxylin-eosin staining, Verhoff ’s elastin
staining, and Goldner’s trichrome staining were performed
for light microscopic examination. Elastin was stained
black using the Verhoff ’s elastin staining, and collagen was
stained green using the Goldner’s trichrome staining.
Photos of the aorta tissue were taken from six different
areas per a rat at a magnification of × 400 with a light
microscope (Zeiss, Jena, Germany). The photo images
were quantitatively analyzed with Image-Pro Plus (Media-
Cybernetics, Silver Spring, MD, USA), a computerized
digital image analyzer. Tunica media thickness was mea-
sured with a digital ruler and a microscopic scale in
hematoxylin-eosin-stained section. The area in black was
semi-automatically measured with Image-Pro Plus in
Verhoff ’s elastin-stained sections for measurement of the
elastin area. The area in green was semi-automatically
measured with Image-Pro Plus in Goldner’s trichrome-
stained section for measurement of the collagen area.
Elastin area fraction was calculated by dividing the elastin
area by the total sampling area, and collagen area fraction
was calculated by dividing the collagen area by the totaltion of drugs
BW2 (g) ΔBW/BW1 × 100 (%)
289.5 (265.5–296.5) 60 (54–62)
262 (247–266) 40 (27–43)
235.5 (239.5–287) 38 (26–71)
224 (210–244.5) 40 (22–42)
ation of drugs, ΔBW BW2 − BW1, C control, AD adriamycin-treated,
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dividing the collagen area by the elastin area.
Electron microscopic examination
The aortic tissue was fixed in 2.5% phosphate-buffered
glutaraldehyde for 2 h and fixed in 1% osmium tetroxide
and then dehydrated in serial alcohol. The aortic tissue
was embedded in araldite and sectioned. After staining
with toluidine blue, the aortic tissue sections were ob-
served under microscope for precise location to cut forFigure 2 Hematoxylin-eosin-stained section and tunica media thickne
CA group, and AD + CA group. (B) Tunica media thickness within the aorta in
AD + CA, adriamycin + candesartan-treated. p values were corrected by Dunnultrathin sections. The endothelial and medial areas of
the aorta were observed with an electron microscope
(EM, Zeiss) at magnifications of × 8,000 and × 16,000,
respectively.
Statistical analysis
Because of nonnormal distribution of data, the results
were expressed as median (interquartile range). Kruskal-
Wallis test was used for comparison of baseline character-
istics of continuous variables between the four groups. Forss. (A) Hematoxylin-eosin-stained section (×400) in C group, AD group,
each group. C, control; AD, adriamycin-treated; CA, candesartan-treated;
ett method.
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Dunnett comparisons between two groups: [8] the C
group and the AD group, between the C group and the
CA group, between the AD group and the AD+CA
group, between the CA group and the AD+CA group,
and between the C group and the AD+CA group. A
p value and Dunnett-corrected p value (pDun) <0.05 was
considered statistically significant. The data were analyzed
using the IBM SPSS ver. 20.0 (IBM Co., Armonk, NY,Figure 3 Verhoff’s elastin stained section and elastin area fraction. (A
group, and AD + CA group. (B) Elastin area fraction within the aorta in each
AD + CA, adriamycin + candesartan-treated. p values were corrected by DunUSA) and R Package ver. 2.0 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
All of the 24 rats survived throughout the study period.
There were no significant differences in body weights at
the beginning of the study between the groups (p = 0.270)
(Table 1). However, the rats in the AD group, the CA
group, and the AD+CA group had a tendency to have) Verhoff’s elastin-stained section (×400) in C group, AD group, CA
group. C, control; AD, adriamycin-treated; CA, candesartan-treated;
nett method.
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although there was no statistical significance (p = 0.223)
(Table 1). There were no complications of intraperitoneal
injection or oral administration. In hematoxylin-eosin-
stained section, the tunica media thickness were 121.0 μm
(range, 105.25 to 126.0 μm), 127.25 μm (range, 121.0 to
137.75 μm), 95.25 μm (range, 87.0 to 100.25 μm), and
89.0 μm (range, 80.75 to 104.75 μm) in the C group, the
AD group, the CA group, and the CA +AD group, re-
spectively. Tunica media thickness in the CA group wasFigure 4 Goldner’s trichrome stained section and collagen area fracti
group, CA group, and AD + CA group. (B) Collagen area fraction within the
candesartan-treated; AD + CA, adriamycin + candesartan-treated. p values wsignificantly lesser than that in the C group (pDun = 0.024).
Tunica media thickness in the AD+CA group was signifi-
cantly lesser than that in the AD group (pDun = 0.016)
(Figure 2). However, there were no significant differences
in tunica media thickness between the C group and the
AD group and between the CA group and the AD+CA
group. In Verhoff ’s elastin-stained section, the elastin area
fraction were 0.15 (range, 0.08 to 0.19), 0.07 (range, 0.04
to 0.09), 0.14 (range, 0.10 to 0.17), and 0.08 (range, 0.06 to
0.11) in the C group, the AD group, the CA group, andon. (A) Goldner’s trichrome-stained section (×400) in C group, AD
aorta in each group. C, control; AD, adriamycin-treated; CA,
ere corrected by Dunnett method.
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tendency of lower elastin area fraction than in the C group
(pDun = 0.086). And the elastic area fraction in the AD+
CA group was significantly lesser than that in the CA
group (pDun = 0.018) (Figure 3). However, there were no
significant differences in the elastin area fraction between
the C group and the CA group and between the AD group
and the AD+CA group. In Goldner’s trichrome-stained
section, the collagen area fraction were 0.15 (range, 0.13
to 0.19), 0.15 (range, 0.14 to 0.16), 0.14 (range, 0.14 to
0.15), and 0.12 (range, 0.11 to 0.14) in the C group, the
AD group, the CA group, and the AD+CA group, re-
spectively. The collagen area fraction in AD+CA group
was significantly lower than that in the C group and the
AD group (pDun = 0.041 and 0.031, respectively) (Figure 4).
Collagen/elastin ratio were 0.97 (range, 0.77 to 2.24), 2.19
(range, 1.77 to 4.09), 1.06 (range, 0.82 to 1.46), and 1.54
(range, 1.20 to 2.08) in the C group, the AD group, the
CA group, and the CA +AD group, respectively. There
were no significant differences in collagen/elastin ratio
between the C group and the AD group (p = 0.093),
between the C group and the CA group (p = 0.589), bet-
ween the AD group and the AD+CA group (p = 0.240),
and between the CA group and the AD+CA group
(p = 0.180) (Figure 5). In electron microscopic exami-
nation of the endothelial cells, we observed intact endo-
thelial layers of the aorta in nine rats (three rats of the C
group, one rat of the AD group, three rats of the CA
group, and two rats of the AD+CA group). There were
no significant findings in the endothelial cells in the
electron microscopic examination. In electron micro-
scopic examination of the endothelial layers, there wereFigure 5 Collagen/elastin within the aorta in each group. C, control;
AD, adriamycin-treated; CA, candesartan-treated; AD + CA, adriamycin +
candesartan-treated.cytoplasmic vacuoles and degeneration of nuclei in a rat
in the AD group (Figure 6). No specific changes were de-
tected in the other groups.Discussion
This pilot study demonstrated that the adriamycin-
treated groups had a tendency of lower elastin area
fraction than the adriamycin-untreated groups. And can-
desartan decreased the thickness of tunica media in the
aorta in adriamycin-treated and adriamycin-untreated
rats and the quantity of collagen fibers in the aorta of
adriamycin-treated rats. According to the results of the
present study, adriamycin had a tendency of reduced
quantity of elastin fibers in the aorta. As a result, elas-
tance of the aorta could decrease and aortic stiffness
could increase [9]. Decreased elastance and increased
stiffness of the aorta mean pathologic processes and
structural remodeling of the aorta. It could aggravate
hypertension and cause target organ damage including
left ventricular hypertrophy [10,11]. Decrement of aortic
elastance could result in aggravation of adriamycin-
induced cardiotoxicity by myocardial fibrosis and struc-
tural remodeling. In addition, candesartan decreased the
tunica media thickness and the quantity of collagen fi-
bers in the aorta in the present study. It was because,
generally, angiotensin receptor blockers have the effects
of mitigating fibrosis by decreasing thickness of tunica
media and collagenogenesis. Reduction of the quantity
of collagen fibers means mitigation of fibrosis and re-
verse of structural remodeling of the aorta. Decrease of
tunica media thickness could be relative to reverse of
structural remodeling of the aorta. However, candesartan
could not show the mitigation of decrement of elastin
fibers by adriamycin.Figure 6 Cytoplasmic vacuoles (arrow) and degenerative
nucleus (arrow head) in the endothelial cells in the AD group.
Electron microscopy, ×8,000. AD, adriamycin-treated.
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myopathy and vasculopathy, drugs that have an effect on
the fibrotic process are essential for the treatment of car-
diomyopathy and vasculopathy. Angiotensin converting
enzyme inhibitors or angiotensin receptor blockers can
regulate the renin-angiotensin-aldosterone system and
ameliorate the fibrotic process [6]. In addition, it was
reported that spironolactone, an aldosterone receptor
blocker, and torasemide, a loop diuretic, can reduce
fibrosis [12,13].
Because the aorta is directly connected to the heart, the
heart and aorta often share the same pathophysiologic pro-
cesses. It has been reported that adriamycin induces aortic
toxicity [14]. However, the mechanisms of adriamycin-
induced aortopathy are not known in detail. The suggested
mechanisms of adriamycin-induced vasculopathy were en-
dothelial dysfunction [15-18], suppression of endothelin-1
in endothelial cells [19], degeneration of endothelial struc-
tures [14], apoptosis of the endothelial cells [20], en-
hancement of procoagulant activity [21], smooth muscle
dysfunction, and dysregulation of its calcium contents
[10,22]. In addition, adriamycin could induce not only car-
diovascular toxicity but also nephrotoxicity by alteration of
glomerular endothelial cells [16,23].
Usually, injection of adriamycin induces retardation of
weight gain [7]. In this study, adriamycin- or candesartan-
treated rats reduced weight gain compared with rats in
control group, although there was no statistical signifi-
cance. In adriamycin-treated rats, it could be because
adriamycin has systemic toxicity. It has reported that inci-
dence of gastrointestinal adverse effects of candesartan
was 1% in human study [24]. In adriamycin-treated rats,
reduced weight gain might be due to gastrointestinal ad-
verse effects of candesartan.
We have shown in the previous report that collagen in
the myocardium significantly increased in adriamycin-
induced cardiomyopathy rat model [7]. However, col-
lagen area fraction between the C group and the AD
group was not significantly different in the present
study. It could be because the mechanisms of aortopathy
could be different from those of cardiomyopathy and be-
cause the numbers of rats and the duration from the
drug administration to sacrifice could be short.
In this study, ultramicroscopic structural changes were
not obvious. It might be because the adriamycin-induced
microscopic changes in the aorta were slower than those
in cardiomyopathy due to the extracellular matrix of the
aorta. It might be because the rats in the present study
were too young to present the microscopic pathologic
processes including atherosclerotic changes.
We had some limitations of the present study. We could
not confirm the development of cardiomyopathy because
we did not perform echocardiography in the rats. We
could not show microscopic and ultramicroscopic changesof endothelial cells by adriamycin and candesartan be-
cause the endothelial layers were damaged in the pro-
cesses of fixation and staining.
Conclusions
Adriamycin had a tendency of decreasing the quantity of
elastin fibers, and candesartan cannot mitigate the ef-
fects of adriamycin on elastin fibers. In oncology clinic,
physicians should be cautious about not only adriamycin-
induced cardiotoxicity but also adriamycin-induced vas-
cular changes. Further studies are necessary to evaluate
the effects of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers on the adriamycin-induced
vascular changes.
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